

CURRICULUM VITAE

1. Biographical Details

Title	Dr. med.
First name	Johannes
Name	Hartl
Current position	Specialist internal medicine
Current institution(s)/site(s), country	First Medical Centre, University Hospital Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20251, Germany
Identifiers/ORCID	https://orcid.org/0000-0002-4037-9938

2. Education / Training

Since 06/2020	Master of Public Health, London School of Hygiene and Tropical Medicine (LSTHM), University of London
02/2014	Doctorate, University of Regensburg, supervisor: Prof. Dr. Reiner Wiest
10/2005 – 10/2012	Medicine, University of Regensburg (UKR)
01/2010- 10/2010	Universidad de Desarrollo, Santiago de Chile (Exchange Program)

3. Professional Experience

Since 03/2013	University Hospital Hamburg-Eppendorf (UKE), First Medical Centre, Directors: Prof. Ansgar W. Lohse and Prof. Samuel M. Huber
01/2018-04/2020	Postdoctoral Fellowship (DFG-funded), New York University (NYU), PI: Prof. Boris Reizis
06/2023	Board certification for Internal Medicine (Facharzt Innere Medizin)

4. Honors and Awards

02/2016	Dr. Martini-Award, Award dedicated to young investigators for outstanding translational research; Subject: " <i>Predictors of relapse after drug withdrawal in autoimmune hepatitis</i> "
10/2012	Honour for excellent Graduation in Medicine, University of Regensburg (Final mark: 1.0, among the best 1% in Germany)

5. Secured Funding

2023-2026	DFG Research grant, 3 years, approx. 300,000 EUR (HA 8440/3-1)
2023-2026	BMBF-funded Advanced Clinical Scientist Program (iSTAR) UKE, approx. 1,000,000 EUR
2018-2020	DFG Research grant, 3 years, approx. 200,000 EUR (HA 8440/1-1)
01/2016	Deutsche Leberstiftung, approx. 10,000 EUR
2015-2018	Clinical Scientist Program University Medical Center Hamburg Eppendorf, 50% Clinical Leave for 3 years

6. Memberships

Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

European Association for the Study of the Liver (EASL)
German Association for the Study of the Liver (GASL)
European Reference Network (ERN) RARE-Liver

7. Selected Publications

Ten selected publications (original manuscripts, first-authorship):

1. Hartl J, Wehmeyer M, Shaima A, Sebode M, Weidemann S, Ptashynska A, Weiler-Normann C, Schramm S, Lohse AW, Krech T, Schrader J. Right and left liver lobe biopsies by minilaparoscopy reveal clinically significant sampling error in staging and grading of autoimmune hepatitis. **Liver Int** 2023;43:1269-1276. doi: 10.1111/liv.15583
2. Hartl J*, R  ther DF*, Duengelhof P, Brehm TT, Steinmann S, Weltzsch JP, Glaser F, Sterneck M, Sebode M, Weiler-Normann C, L  tgehetmann M, Schaub GM, Haag F, Schramm C, Schulze zur Wiesch J, Lohse AW. Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis. **Liver Int** 2023;43:393-400. doi: 10.1111/liv.15368. *Shared first authorship
3. Duengelhof P*, Hartl J*, R  ther DF, Steinmann S, Brehm TT, Weltzsch JP, Glaser F, Schaub GM, Sterneck M, Sebode M, Weiler-Normann C, Addo MM, L  tgehetmann M, Haag F, Schramm C, Schulze zur Wiesch J, Lohse AW. SARS-CoV-2 Vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. **United European Gastroenterol J** 2022;10(3):319-329. *Shared first authorship doi: 10.1002/ueg2.12218. *Shared first authorship
4. Hartl J, Serpas L, Wang Y, Rashidfarrokhi A, Perez OA, Sally B, et. al. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. **J Exp Med** 2021;218(5). doi: 10.1084/jem.20201138.
5. Hartl J, Miquel R, Zachou K, Wong GW, Asghar A, Pape S, Sebode M, Peiseler M, Zenouzi R, Ehlken H, Krech Till, Weiler-Normann C, Drenth JPH, Oo YH, Dalekos GN, Heneghan M, Schramm C, Lohse AW. Features and outcome of AIH patients without elevation of IgG. **JHEP Rep** 2020;2(3):100094. doi: 10.1016/j.jhepr.2020.100094.
6. Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, von Felden J, Weiler-Normann C, Schramm C, Lohse AW. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. **J Hepatol** 2018;68(4):754-763. doi: 10.1016/j.jhep.2017.11.020.
7. Hartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, H  bener S, Pannicke N, Weiler-Normann C, Quaas A, Lohse AW, Schramm C. Validation of transient elastography in autoimmune hepatitis: timing determines the impact of inflammation and fibrosis. **J Hepatol** 2016;65(4):769-75 doi: 10.1016/j.jhep.2016.05.023.
8. Hartl J, Otto B, Madden RG, Webb G, Woolson W, Kriston L, Vettorazzi E, Lohse AW, Dalton HR, Pische S. Hepatitis E Seroprevalence in Europe: A Meta-Analysis. **Viruses** 2016;8:211. doi: 10.3390/v8080211.
9. Hartl J, Dietrich P, Moleda L, M  ller-Schilling Martina, Wiest R. Neuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries. **Liver Int** 2015;35:2556-63. doi: 10.1111/liv.12874.
10. Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, Zenouzi R, Glaubke C, Lohse AW, Schramm C. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. **J Hepatol** 2015;62(3):642-6. doi: 10.1016/j.jhep.2014.10.018.